Incyte presents late-breaking data from Phase 2 trial evaluating povorcitinib

Incyte announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib, an oral JAK1 inhibitor, in adult patients with prurigo nodularis. These data were presented as a late-breaking oral presentation at the American Academy of Dermatology Annual Meeting, held from March 8-12, 2024, in San Diego. The study met its primary endpoint with a greater than or equal to 4-point improvement in itch Numerical Rating Scale score achieved by significantly more patients who received povorcitinib across all dosing groups than those who received placebo at Week 16. Median times to itch NRS4 were 58, 35 and 17 days for patients who received 15, 45 and 75 mg of povorcitinib, respectively, and was not estimable for the placebo arm. The secondary endpoints of the study were also met. At Week 16, 13.9%, 30.6% and 48.6% of patients who received 15, 45 and 75 mg of povorcitinib, respectively, achieved an Investigator’s Global Assessment Treatment Success score of 0 or 1 with a greater than or equal to2-grade improvement from baseline, versus 5.4% of patients who received placebo. Further, 8.3%, 22.2% and 35.1% of patients who received 15, 45 and 75 mg of povorcitinib, respectively, achieved both itch NRS4 and IGA-TS at Week 16, versus 2.5% of patients who received placebo. Povorcitinib was generally well-tolerated, and the safety profile was consistent with previously reported data.